Natural Bcl-2 inhibitor (-)- Gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2263-2268

  Ni, Zhenhong ^a   Dai, Xufang ^b   Wang, Bin ^a   Ding, Wen ^a   Cheng, Panke ^a   Xu, Liang ^c   Lian, Jiqin ^a   He, Fengtian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

( ) Gossypol; Autophagy; HMGB1; ROS

Indexed keywords

ACETYLCYSTEINE; GOSSYPOL; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BURKITT LYMPHOMA; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MAXIMUM TOLERATED DOSE; MITOCHONDRIAL RESPIRATION; PREMEDICATION; PRIORITY JOURNAL;

ANTIOXIDANTS; APOPTOSIS; AUTOPHAGY; BURKITT LYMPHOMA; CELL LINE, TUMOR; CYTOSOL; GOSSYPOL; HMGB1 PROTEIN; HUMANS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84884482589     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.775437     Document Type: Article

References (45)

1. Blum KA, Lozanski G, Byrd JC. A dult Burkitt leukemia and lymphoma. Blood 2004; 104: 3009-3020.
2. Balakrishnan K, Burger JA, Wierda WG, et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113: 149-153.
3. Akagunduz O, Karaca B, Atmaca H, et al. Radiosensitization of hormone-refractory prostate cancer cells by gossypol treatment. J BUON 2010; 15: 763-767.
4. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(+)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4: 13-21.
5. Etxebarria A, Landeta O, Antonsson B, et al. Regulation of antiapoptotic MCL-1 function by gossypol: Mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol 2008; 76: 1563-1576.
6. Meng Y, Li Y, Li J, et al. ( +) Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma 2007; 48: 2204-2212.
7. Kline MP, Rajkumar SV, Timm MM, et al. R -( + )-gossypol (AT- 101) activates programmed cell death in multiple myeloma cells. Exp Hematol 2008; 36: 568-576.
8. Warr MR, Shore GC. Small-molecule Bcl-2 antagonists as targeted therapy in oncology. Curr Oncol 2008; 15: 256-261.
9. Oliver CL, Miranda MB, Shangary S, et al. (+ ) -Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 2005; 4: 23-31.
10. Arnold AA, Aboukameel A, Chen J, et al. Preclinical studies of apogossypolone: A new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008; 7: 20.
11. Liu Q, Wang JJ, Pan YC, et al. [Expression of autophagy-related genes Beclin1 and MAPLC3 in non-small cell lung cancer]. Ai Zheng 2008; 27: 25-29.
12. Macoska JA, Adsule S, Tantivejkul K, et al. - (+ )Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 2008; 58: 323-331.
13. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (+ )-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-2202.
14. Sikora MJ, Bauer JA, Verhaegen M, et al. Anti-oxidant treatment enhances anti-tumor cytotoxicity of ( + )-gossypol. Cancer Biol Ther 2008; 7: 767-776.
15. Gao P, Bauvy C, Souquere S, et al. The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 2010; 285: 25570-25581.
16. Voss V CS, Lang V, Ronellenfitsch MW, et al. The pan-Bcl-2 inhibitor ( + )-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 2010; 8: 15-23.
17. Lian J, W u X, H e F, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 2011; 18: 60-71.
18. Sung B, Ravindran J, Prasad S, et al. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 2010; 285: 35418-35427.
19. Balakrishnan K, Wierda WG, Keating MJ, et al. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008; 112: 1971-1980.
20. Lian J, N i Z, Dai X, et al. Sorafenib sensitizes (+ )-gossypolinduced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol Cancer Ther 2012; 11: 416-426.
21. Chen Y, Azad MB, Gibson SB. Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol 2010; 88: 285-295.
22. Li X, Lu Y, Pan T, et al. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010; 6: 1066-1077.
23. Yan HL, Xue G, Mei Q, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009; 28: 2719-2732.
24. Yang X, Zhang Y, Zhang L, et al. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett 2008; 271: 281-293.
25. Paglin, H ollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001; 61: 439-444.
26. Kang R, Livesey KM, Zeh HJ 3rd, et al. HMGB1 as an autophagy sensor in oxidative stress. Autophagy 2011; 7: 904-908.
27. Dalby KN, Tekedereli I, Lopez-Berestein G, et al. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6: 322-329.
28. Baehrecke EH. Autophagy: Dual roles in life and death? Nat Rev Mol Cell Biol 2005; 6: 505-510.
29. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy 2006; 2: 85-90.
30. Lian J, Karnak D, Xu L. The Bcl-2-Beclin 1 interaction in (+ )-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy 2010; 6: 1201-1203.
31. Maiuri MC, Criollo A, Tasdemir E, et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007; 3: 374-376.
32. Dewaele M, Maes H, Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010; 6: 838-854.
33. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 2007; 17: 422-427.
34. Low ICC, Kang J, Pervaiz S. Bcl-2: A prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 2011; 15: 2975-2987.
35. Arinbasarova AY, Medentsev AG, Krupyanko VI. Gossypol inhibits electron transport and stimulates ROS generation in Yarrowia lipolytica mitochondria. Open Biochem J 2012; 6: 11-15.
36. Wong CH, Iskandar KB, Yadav SK, et al. Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROSdependent ERK and JNK activation. PLoS One 2010; 5: E9996.
37. Yuan Y, Xue X, Guo R-B, et al. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROSdependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther 2012; 18: 536-546.
38. Walker T, Mitchell C, Park MA, et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 2009; 76: 342-355.
39. Kim KW, Moretti L, L u B. M 867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS One 2008; 3: E2275.
40. Jia L, Coward LC, Kerstner-Wood CD, et al. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol 2008; 61: 63-73.
41. Wu DF, Yu YW, Tang ZM, et al. Pharmacokinetics of ( + /+)-, ( + )+, and ( + )-gossypol in humans and dogs. Clin Pharmacol Ther 1986; 39: 613-618.
42. Schrier BP, Lichtendonk WJ, Witjes JA. The effect of N-acetyl-L-cysteine on the viscosity of ileal neobladder mucus. World J Urol 2002; 20: 64-67.
43. Conesa EL, Valero F, Nadal JC, et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 2001; 281: R730-R737.
44. Shimamoto K, Hayashi H, Taniai E, et al. Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats. J Toxicol Sci 2011; 36: 775-786.
45. Barkholt L, Remberger M, Hassan Z, et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 785-790.